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AMPK is a metabolic sensor that helps maintain
cellular energy homeostasis. Despite evidence link-
ing AMPK with tumor suppressor functions, the role
of AMPK in tumorigenesis and tumor metabolism
is unknown. Here we show that AMPK negatively
regulates aerobic glycolysis (the Warburg effect) in
cancer cells and suppresses tumor growth in vivo.
Genetic ablation of the a1 catalytic subunit of AMPK
accelerates Myc-induced lymphomagenesis. Inacti-
vation of AMPKa in both transformed and nontrans-
formed cells promotes a metabolic shift to aerobic
glycolysis, increased allocation of glucose carbon
into lipids, and biomass accumulation. These meta-
bolic effects require normoxic stabilization of the
hypoxia-inducible factor-1a (HIF-1a), as silencing
HIF-1a reverses the shift to aerobic glycolysis and
the biosynthetic and proliferative advantages con-
ferred by reduced AMPKa signaling. Together our
findings suggest that AMPK activity opposes tumor
development and that its loss fosters tumor progres-
sion in part by regulating cellular metabolic pathways
that support cell growth and proliferation.
INTRODUCTION
Genetic lesions that drive cancer progression affect key biolog-
ical control points, including cell-cycle entry, DNA damage
checkpoints, and apoptosis. However, the initiation of uncon-
trolled proliferation also presents a significant bioenergetic chal-Celllenge to cancer cells; they must generate enough energy and
acquire or synthesize biomolecules at a sufficient rate to meet
the demands of proliferation. It is now appreciated that many
of the predominant mutations observed in cancer also control
tumor cell metabolism (Levine and Puzio-Kuter, 2010), suggest-
ing that oncogene and tumor suppressor networks influence
metabolism as part of their mode of action. One of the primary
metabolic changes observed in proliferating cells is increased
catabolic glucose metabolism. Many tumor cells adopt a meta-
bolic phenotype characterized by high rates of glucose uptake
and lactate production regardless of oxygen concentration,
a phenomenon commonly referred to as the ‘‘Warburg effect’’
(Vander Heiden et al., 2009). While the energetic yield per mole-
cule of glucose is much lower for aerobic glycolysis compared to
oxidative phosphorylation (OXPHOS), the metabolic shift toward
the Warburg effect appears to confer both bioenergetic and
biosynthetic advantages to proliferating cells by promoting
increased nonoxidative ATP production and generating meta-
bolic intermediates from glucose that are important for cell
growth (DeBerardinis et al., 2008).
Appreciation of the generality of the Warburg effect in cancer
has stimulated the broader concept that a ‘‘metabolic transfor-
mation’’ accompanies tumorigenesis (Jones and Thompson,
2009). However, the metabolic control points and signal trans-
duction pathways that regulate theWarburg effect during tumor-
igenesis and their importance to tumor progression in vivo
remain poorly defined. The AMP-activated protein kinase
(AMPK) is a highly conserved Ser/Thr protein kinase complex
that plays a central role in the regulation of cellular energy
homeostasis. AMPK is activated in response to declining fuel
supply and functions in the decision to allocate nutrients toward
catabolic/energy-producing or anabolic/growth-promoting met-
abolic pathways (Hardie, 2011). From a metabolic standpoint,
AMPK promotes ATP conservation under conditions ofMetabolism 17, 113–124, January 8, 2013 ª2013 Elsevier Inc. 113
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such as autophagy (Egan et al., 2011; Kim et al., 2011) and
inhibiting anabolic processes including lipid biosynthesis
(Davies et al., 1990), TORC1-dependent protein biosynthesis
(Gwinn et al., 2008; Inoki et al., 2003), and cell proliferation (Im-
amura et al., 2001; Jones et al., 2005). AMPK activity has been
recently linked to stress resistance and survival in tumor cells
(Jeon et al., 2012; Liu et al., 2012).
Due to its involvement in cellular stress resistance, AMPK has
been linked to the regulation of tumorigenesis (Shackelford and
Shaw, 2009). The upstream AMPK-activating kinase LKB1 is a
tumor suppressor gene inactivated in patients with Peutz-
Jegher’s syndrome (Alessi et al., 2006), a condition that predis-
poses patients to gastrointestinal polyps and malignant tumors
(Giardiello et al., 1987; Hearle et al., 2006). Cells lacking LKB1
display defective energy-dependent AMPK activation (Hawley
et al., 2003; Shaw et al., 2004b). Additional evidence supporting
a tumor suppressor function for AMPK is derived from experi-
ments with the glucose-lowering drug metformin, which acts in
part by activating AMPK (Zhou et al., 2001). Treatment of animals
harboring tumor xenografts or naturally arising lymphomas with
metformin can delay tumor progression (Buzzai et al., 2007;
Huang et al., 2008). However, to date the role of AMPK in tumor-
igenesis and tumor metabolism has remained unclear.
In this work, we demonstrate that loss of AMPK signaling
cooperates with Myc to accelerate tumorigenesis. Moreover,
silencing AMPKa in both transformed and nontransformed cells
results in a switch to aerobic glycolysis (Warburg effect) in the
absence of energetic crisis. This metabolic shift is characterized
by increased glucose uptake, redirection of carbon flow toward
lactate, increased flux of glycolytic intermediates toward lipid
biosynthesis, and an increase in net biomass (size). Induction
of this metabolic shift is dependent on HIF-1a, as silencing of
HIF-1a by shRNA ablates the effects of AMPKa loss on aerobic
glycolysis, biosynthesis, and tumor growth in vivo. Our findings
indicate that AMPK is a metabolic sensor essential for the coor-
dination of metabolic activities that support cell growth and
proliferation in cancer cells, and that disruption of AMPK
signaling promotes metabolic reprogramming of cancer cells
to drive the Warburg effect and influence tumor development
and progression in vivo.
RESULTS
Loss of AMPKa1 Accelerates Myc-Driven
Lymphomagenesis
AMPK lies downstream (Hawley et al., 2003; Shaw et al., 2004b)
and upstream (Inoki et al., 2003) of known tumor suppressors
(LKB1 and TSC2, respectively), but its role in tumorigenesis
has remained unclear. To address this question, we generated
Em-Myc transgenic mice (Adams et al., 1985) harboring a muta-
tion in the gene that encodes AMPKa1 (prkaa1), which is the sole
catalytic subunit expressed in B lymphocytes (Figure S1A avail-
able online). Latency to tumor development was monitored by
palpation, and both tumor-free survival and overall life span
were monitored. Compared to Em-Myc control mice, Em-Myc
animals lacking AMPKa1 displayed accelerated lymphomagen-
esis with a median tumor onset of 7 weeks (Figure 1A) and
a maximum overall survival rate of 20 weeks (Figure S1B).114 Cell Metabolism 17, 113–124, January 8, 2013 ª2013 Elsevier InEm-Myc mice heterozygous for AMPKa1 displayed an interme-
diate phenotype, with a median tumor onset of 10 weeks (Fig-
ure 1A). Lymph node tumors isolated from Em-Myc/a1+/+ and
Em-Myc/a1/ mice displayed prominent B220/CD45R staining,
indicating that tumors arising in these animals were of B cell
origin (Figure S1C); however, all AMPKa1-deficient B220+
lymphomas examined lacked surface immunoglobulin (sIg)
expression, suggesting that these tumors were pre-B cell
tumors, rather than mature B cell tumors (Figure S1C).
To assess whether the accelerated tumor onset observed in
Em-Myc/a1/ animals was due to a cell intrinsic effect of
AMPKa1 deficiency in B cells, we generated chimeric mice using
Em-Myc/a1+/+ or Em-Myc/a1/ hematopoietic stem cells (HSCs)
to reconstitute lethally irradiated wild-type mice (C57BL/6 back-
ground). All animals reconstituted with Em-Myc/a1/ HSCs
developed palpable lymphomas within 9 weeks of reconstitu-
tion, while only 20% of animals receiving Em-Myc/a1+/+ HSCs
developed tumors 12 weeks after reconstitution (Figure 1B).
These data establish that specific loss of AMPKa1 in B cells
can promote accelerated Myc-driven lymphomagenesis.
While lymph node tumors from both genotypes looked histo-
logically similar by hematoxylin and eosin staining (Figure S1D),
Em-Myc/a1/ lymphomas displayed increased proliferation
marker Ki-67 staining in situ (Figure 1C). Immunohistochemical
(IHC) analysis revealed no major differences in tumor vasculari-
zation (measured by CD31 staining) or apoptosis (IHC for
cleaved caspase-3) between AMPKa1-deficient and control
Em-Myc tumors (Figure S1E). We next silenced AMPKa1 in
primary Em-Myc lymphoma cells using short hairpin RNA
(shRNA; Figure S1F) andmeasured the impact of AMPKa1 levels
on cell proliferation using an in vitro competition assay. Primary
Em-Myc lymphoma cells were transduced with retroviral vectors
coexpressing GFP and control or AMPKa1-specific shRNAs,
and the percentage of GFP+ cells remaining after 6 days of
culture was determined by flow cytometry. AMPKa1 shRNA-ex-
pressing cells displayed a competitive growth advantage in vitro
over cells expressing control shRNA (Figure 1D).
Activation of AMPK promotes cell survival in response to
metabolic stress (Bungard et al., 2010; Buzzai et al., 2007;
Jeon et al., 2012). To determine whether loss of AMPK renders
Em-Myc tumors sensitive tometabolic stress, we treated Em-Myc
lymphoma cells expressing control or AMPKa1 shRNAs with the
glycolytic inhibitor 2-deoxyglucose (2-DG) and measured cell
viability after 24 hr. AMPKa1 shRNA-expressing lymphomas dis-
played normal viability under standard growth conditions but
increased cell death in the presence of 2-DG (Figure 1E).
Together, these data suggest that loss of AMPKa1 can enhance
tumor development driven by oncogenic Myc in vivo but is
required to maintain tumor cell viability.
We next explored putative altered signaling events in
AMPKa1-deficient lymphomas by IHC analysis of tumor
sections. AMPKa, phospho-AMPKa, and phospho-ACC
(pACC) expression in tumor-bearing lymph nodes confirmed a
complete loss of AMPK signaling in Em-Myc/a1/ tumors (Fig-
ure S1G). Similar to that observed in Lkb1+/ tissues (Shackel-
ford et al., 2009; Shaw et al., 2004a), tumor tissue from
Em-Myc/a1/ mice displayed increased staining for S6 and
4E-BP1 phosphorylation (Figure 1F), suggesting an increase in
basal TORC1 signaling in AMPKa-null lymphomas in vivo.c.
A B
C D E
GF
Figure 1. AMPKa1 Cooperates with Myc to
Promote Lymphomagenesis
(A) Kaplan-Meier curves showing latency to tumor
development in Em-Myc transgenic mice deficient
(a1/, red), heterozygous (a1+/, blue), or wild-
type (a1+/+, black) for AMPKa1.
(B) Kaplan-Meier curves showing latency to tumor
development in chimeric mice reconstituted
with Em-Myc/a+/+ (a1+/+, black) or Em-Myc/a1/
(a1/, red) HSCs (n = 5 per group).
(C) Representative histological sections of Em-
Myc/a+/+ and Em-Myc/a1/ lymphomas stained
for the proliferation marker Ki-67.
(D) Competition assay of Em-Myc lymphoma cells
expressing GFP and control (Ctrl) or AMPKa1-
specific (a1) shRNAs. Data are expressed as the
fold enrichment in GFP+ to GFP– cells after 6 days
of growth.
(E) Viability of control (Ctrl) or AMPKa1 shRNA-
expressing Em-Myc lymphomas cells after 24 hr
treatment with 2-deoxyglucose (2-DG, 15 mM).
Error bars represent the SEM.
(F) Immunohistochemical analysis of representa-
tive Em-Myc/a+/+ and Em-Myc/a1/ lymphomas
stained with antibodies to detect TORC1 activity
(total and phospho-ribosomal S6 (pS6, S240/244),
or total and phospho-4EBP1 (p4EBP1, S37/46).
(G) Immunoblot analysis of primary Em-Myc/a+/+
or Em-Myc/a1/ lymphomas. Whole-cell lysates
prepared from sorted primary lymphoma cells
were analyzed by immunoblot with the indicated
antibodies. Each lane represents an independent
tumor. Lysates from nontransformed B cells
isolated from Em-Myc-negative mice are shown.
**p < 0.01, ***p < 0.001. See also Figure S1.
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lymphoma cells isolated immediately ex vivo from tumor-bearing
lymph nodes. Both TORC1 and AMPK activity (as determined by
ACC phosphorylation) were elevated in Em-Myc lymphoma cells
compared to normal B cells (Figure 1G). When comparing Em-
Myc/a1+/+ and Em-Myc/a1/ lymphomas directly, pACC levels
were ablated in a1/ tumors, while TORC1 activity was
increased in a1/ tumors with some variability in levels of
both S6 and 4E-BP1 phosphorylation between a1/ tumor
samples (Figure 1G).
Loss of AMPKa Signaling Enhances the Warburg Effect
in Cancer Cells
AMPK sits at a central node in the regulation of catabolic and
anabolic metabolism (Hardie et al., 2012). To address the role
of AMPK in regulating the metabolism of lymphoma cells, we
conducted a targeted metabolomic analysis of Em-MycCell Metabolism 17, 113–124lymphoma cells using nuclear magnetic
resonance (NMR) spectrometry. Employ-
ing a stringent statistical cutoff (p < 0.01)
and metabolites displaying a 2-fold
change in abundance, we identified 13
metabolites showing differential abun-
dance in shAMPKa1 lymphoma cells (Fig-
ure 2A). By these criteria, glucosewas theonly metabolite significantly decreased in shAMPKa1 lymphoma
cells, while lactate displayed the greatest increase (Figure 2A).
Lymphomas expressing AMPKa1 shRNA displayed an elevated
extracellular acidification rate (ECAR, Figure 2B), an index of
lactate production (Wu et al., 2007), but displayed no significant
difference in their oxygen consumption rate (OCR; Figures 2C
and S2A). AMPKa1 shRNA-expressing Em-Myc lymphoma
cells also displayed increased glucose consumption (Figure 2D)
and lactate production (Figure 2E) relative to control lymphoma
cells, a metabolic signature consistent with the Warburg effect.
To assess whether reducing AMPK activity is sufficient to
enhance the Warburg effect in cancer cells we silenced AMPK
in two independent cell lines, H1299 (non-small-cell lung carci-
noma) and HCT116 (colon carcinoma). Expression of shRNAs
targeting both the a1 and a2 subunits of AMPK reduced total
AMPKa protein expression in these cell lines (Figures 2F and
2G), and AMPKa silencing promoted a significant increase in, January 8, 2013 ª2013 Elsevier Inc. 115
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Figure 2. Loss of AMPK Signaling Enhances
the Warburg Effect in Cancer Cells
(A) NMR metabolite profile of AMPKa-deficient
lymphomas. Data are expressed as relative
metabolite levels for shAMPKa1- versus shCtrl-
expressing cells (p < 0.01) for samples in quintu-
plicate. Open bars, decreased metabolites; closed
bars, increased metabolites.
(B and C) Extracellular acidification rate (ECAR) (B)
and oxygen consumption rate (OCR) (C) for prolif-
erating shControl (Ctrl) or shAMPKa1 (a1) Em-Myc
lymphoma cells. Data represent the mean ± SEM
for quadruplicate samples.
(D and E) Glucose consumption (D) and lactate
production (E) of shControl (Ctrl) or shAMPKa1 (a1)
Em-Myc lymphoma cells grown as in (B) and (C).
(F) Immunoblot ofAMPKaT172phosphorylationand
total AMPKa levels in H1299 cell clones expressing
control (shCtrl) or AMPKa1/a2-specific shRNAs
following treatment with Metformin (5 mM, 1 hr).
(G) Knockdown of AMPKa1 anda2 inHCT116 cells.
(H and I) ECARofH1299 (H) orHCT116 (I) cell clones
expressing control (shCtrl) or AMPKa-specific (a1/
a2) shRNAs grown under standard conditions.
Error bars represent the SEM. *p < 0.05, ***p <
0.001. See also Figure S2.
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(Figure 2I). Lactate production was also elevated in H1299 and
HCT116 cells expressing AMPKa shRNA (Figures S2B and
S2C). Taken together with our observations using AMPKa1
shRNA-expressing Em-Myc lymphoma cells, these data suggest
that downregulation of AMPK signaling is sufficient to enhance
the Warburg effect in transformed cells.
Loss of AMPK Signaling Promotes Increased ATP Levels
and Anabolic Metabolism
Given the increased metabolic demands of cell proliferation,
we hypothesized that an intact AMPK signaling pathway may
function to coordinate metabolism and biosynthesis in actively
dividing cells. To address this, we generated nontransformed
mouse embryonic fibroblasts (MEFs) deficient for AMPKa. Using
MEFs deficient for prkaa1 and harboring a conditional mutation
for prkaa2 (denoted hereafter as a1/, a2fl/fl), we generated116 Cell Metabolism 17, 113–124, January 8, 2013 ª2013 Elsevier Inc.paired isogenic cell lines that possess or
completely lack AMPK catalytic activity
depending on expression of Cre recombi-
nase (Figure S3A). MEFs lacking AMPKa
(Cre+) displayed increased glucose con-
sumption (Figure S3B), lactate production
(Figure S3C), and ECAR (Figure 3A) rela-
tive to control (Cre–) cells. We next traced
the metabolic fate of 13C-glucose in these
cells, and we found that AMPKa-deficient
cells displayed a progressive increase in
the m+3 isotopologue of lactate (13C3-
lactate) derived from glucose over time
(Figure 3B), corresponding to a 6-fold
increase in the glucose-to-lactate conver-
sion rate.One possibility for the increased ECAR in cells lacking AMPK
activity could be a compensatory response to low cellular energy
triggered by AMPK loss. To address this, we measured the
adenylate energy charge in unstressed, actively growing MEFs
by high-performance liquid chromatography (HPLC). Remark-
ably, cellular ATP levels were elevated in AMPKa-deficient
MEFs relative to controls (Figure 3C). In contrast, the AMP:ATP
ratio was not significantly affected by the loss of AMPK activity
in proliferating cells (Figure 3D), suggesting no significant
change in basal cellular energy charge when AMPKa is absent.
The metabolic shift to the Warburg effect facilitates the redi-
rection of glucose-derived carbon toward biosynthetic pathways
to generate biomass (Vander Heiden et al., 2009), including
extrusion of glucose-derived citrate from the citric acid cycle
(CAC) for lipid biosynthesis (Hatzivassiliou et al., 2005). Consis-
tent with this, total citrate levels were elevated in AMPKa-
deficient cells relative to control cells as determined by gas
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Figure 3. Loss of AMPKSignaling Promotes
Increased Biosynthesis
(A) ECAR of control (Cre–, open bar) or AMPKa-
null (Cre+, closed bar) MEFs cultured under stan-
dard growth conditions. Values shown are the
mean ± SEM for samples in quadruplicate.
(B) Glucose-to-lactate conversion in control (Cre–)
or AMPKa-deficient (Cre+) MEFs. Cells were
cultured with medium containing uniformly labeled
13C-glucose, and enrichment of 13C-lactate (m+3)
in the extracellular medium was measured at the
indicated time points.
(C) ATP content of control (Cre–) or AMPKa null
(Cre+) MEFs as measured by HPLC.
(D) AMP:ATP ratios for cells in (C).
(E) Intracellular citrate levels of control (Cre–) or
AMPKa null (Cre+) MEFs as determined by
GC-MS.
(F) Glucose-derived lipid biosynthesis in control
(Cre–) or AMPKa null (Cre+) MEFs. Cells were
incubated with uniformly labeled 14C-glucose for
72 hr, and radioactive counts in extracted lipids
were measured.
(G) Palmitate oxidation by MEFs expressing control (Ctrl) or AMPKa1/a2 shRNAs. MEFs were grown in the presence (+) or absence (–) of glucose for 24 hr,
followed by culture with [9,10-3H]-palmitic acid and 200 mM etomoxir. Tritiated water produced from palmitate oxidation was measured.
(H) Forward scatter (FSC) of control (Cre–, gray histogram) or AMPKa-deficient (Cre+, open histogram) MEFs.
Error bars represent the SEM. *p < 0.05, ***p < 0.001, ****p < 0.0001. See also Figure S3 and Table S1.
Cell Metabolism
AMPK Negatively Regulates the Warburg Effectchromatography-mass spectrometry (GC-MS) (Figure 3E).
We next measured glucose-dependent lipid biosynthesis by
culturing MEFs with D-[6-14C]-glucose, and we found that
AMPKa-deficient cells displayed increased 14C-labeling in lipids
(Figure 3F). Decreased ACCphosphorylation in AMPKa-null cells
is predicted to contribute to lipid synthesis, but it may also
decrease fatty acid oxidation. Baseline palmitate oxidation re-
mained low in proliferating cells grown under full glucose condi-
tions regardless of AMPK expression (Figure 3G). However, cells
expressing AMPKa shRNA displayed a reduced ability to oxidize
lipid upon complete removal of glucose (Figure 3G), suggesting
that AMPK is required to trigger catabolic lipid metabolism
specifically under nutrient poor conditions.
Consistent with shunting of glucose-derived carbon toward
biosynthesis in proliferating cells, AMPKa-null MEFs displayed
a 20% increase in median cell size as determined by forward
scatter (FSC) with flow cytometry (Figure 3H). TORC1 is a central
regulator of cell size (Laplante and Sabatini, 2009), and AMPK
cannegatively regulate TORC1activity under energy stress (Inoki
et al., 2003; Shaw et al., 2004a). Consistent with this, the AMPK
agonist AICAR suppressed TORC1 activity (as determined by
reduced pS6 and p4E-BP levels) only in cells with wild-type
AMPKa (Figure S3D). Notably, growth factor-dependent
TORC1 activity in cells was similar regardless of AMPKa status
(Figure S3E), suggesting the existence of TORC1-independent
pathways of biomass regulation in AMPKa-deficient cells.
Loss of AMPKa Promotes a Glycolytic Signature
and Increased HIF-1a Expression
Wenext investigated potential mechanisms governing the glyco-
lytic phenotype associated with AMPKa-deficient cells. We first
used quantitative PCR (qPCR) to examine the relative levels of
messenger RNA (mRNA) transcripts encoding for proteins
involved in glycolytic regulation. AMPKa-null MEFs displayed aCellglycolytic gene signature marked by increased mRNA expres-
sion of Aldolase A (aldoa), Lactate dehydrogenase A (ldha),
and pyruvate dehydrogenase kinase 1 (pdk1) (Figures 4A and
S4A), a pattern of gene expression also displayed by shAMPKa1
lymphoma cells (Figure S4B). Elevated Aldolase, LDHA, and
PDK1 protein levels were also detected in AMPKa-deficient
MEFs (Figure 4B) and shAMPKa1 lymphoma cells (Figure 4C).
PDK1 curbs pyruvate flux to Acetyl-CoA and entry into the
TCA cycle by antagonizing the action of the pyruvate dehydroge-
nase (PDH) complex (Kim et al., 2006; Papandreou et al., 2006).
Thus, elevated PDK1 levels observed in AMPKa-deficient cells
may be predicted to affect glucose flux to citrate. To measure
this, we cultured control or AMPKa-null MEFs in medium con-
taining uniformly labeled [13C]-glucose and measured 13C
enrichment in citrate by gas chromatography-mass spectrom-
etry (GC-MS). Glucose-derived pyruvate is converted to Ac-
CoA by PDH. Subsequent condensation of [1,2-13C]-Ac-CoA
with oxaloacetate (OAA) yields citrate with 2 additional mass
units (m+2), while an additional turn through the TCA cycle
produces citrate(m+4). We observed modest increases in levels
of unlabeled citrate in AMPKa null MEFs relative to control cells,
as well as reduced citrate(m+4) labeling from [13C]-glucose (Fig-
ure S4C). 13C enrichment in citrate was similar between control
and AMPKa-null MEFs when [13C]-glutamine was used as
carbon source (Figure S4D).
Several of the enzymes elevated in AMPKa-deficient cells are
known targets of the transcription factor HIF-1a, one of the
central regulators of glycolysis induced by hypoxia (Keith et al.,
2012; Semenza, 2011). We observed elevated HIF-1a protein
levels under normoxia after acute AMPKa deletion in our
isogenic cell lines (Figure 4D), consistent with previous work
demonstrating elevated HIF-1a protein expression in cells with
chronic depletion of AMPKa (Shackelford et al., 2009). More-
over, shRNA-mediated knockdown of AMPKa1 in Em-MycMetabolism 17, 113–124, January 8, 2013 ª2013 Elsevier Inc. 117
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lytic Signature and Increased HIF-1a Ex-
pression
(A) Relative expression of aldoa, ldha, and pdk1
mRNA in control (Cre–, open bar) or AMPKa-null
(Cre+, closed bar) MEFs as determined by qPCR.
Transcript levels were determined relative to actin
mRNA levels and normalized relative to control
(Cre–) cells.
(B and C) Immunoblot analysis of Aldolase, LDHA,
and PDK1 protein levels in whole-cell lysates from
control (Cre–) and AMPKa-null (Cre+) MEFs (B) or
shControl (Ctrl) and shAMPKa1 (a1) -expressing
Em-Myc lymphoma cells (C).
(D and F) Immunoblot of HIF-1a protein levels
in whole-cell lysates from control (Cre–) and
AMPKa-null (Cre+) MEFs (D), shControl (shCtrl)
and shAMPKa1-expressing Em-Myc lymphoma
cells (E), or HCT116 cell clones expressing
control (shCtrl) or AMPKa-specific (shAMPKa1/2)
shRNAs (F). All cells were grown under 20% O2.
(G) Relative hif1a mRNA expression in control
(Cre–) or AMPKa null (Cre+) MEFs as determined
by qPCR.
(H and I) Expression of hif-1a mRNA (H) and
protein levels (I) for control (Cre–) or AMPKa null
(Cre+) MEFs transfected with siRNAs targeting
Raptor. Protein lysates were also analyzed for pS6
and p4EBP levels by immunoblot. Raptor, AMPKa,
and actin levels are shown as controls.
Error bars represent the SEM. **p < 0.01. See also
Figure S4.
Cell Metabolism
AMPK Negatively Regulates the Warburg Effectlymphomas (Figure 4E) or HCT116 cells (Figure 4F) promoted
normoxic HIF-1a protein stabilization. Levels of hif1a mRNA
were unchanged in AMPKa null MEFs relative to controls (Fig-
ure 4G), suggesting that reduction of AMPK activity is sufficient
to increase HIF-1a protein levels in cancer cells under normoxic
conditions independent of mRNA levels.
TORC1 signaling has been linked to control of HIF-1a expres-
sion through differential regulation of its translation (Choo et al.,
2008). To examine the contribution of TORC1 signaling to HIF-1a
stabilization in AMPKa-deficient cells, we silenced the TORC1
binding partner Raptor using small interfering RNA (siRNA).
Treatment with Raptor siRNA significantly reduced hif1a mRNA
levels in both control and AMPKa-deficient MEFs, with the latter
demonstrating a large drop in hif1a mRNA expression upon
Raptor depletion (Figure 4H). Moreover, transient knockdown
of Raptor in AMPKa-deficient MEFs reduced HIF-1a protein
levels (Figure 4I) and reduced the expression of the HIF-1a
targets aldoa (Figure S4E) and ldha (Figure S4F).
AMPKa-Dependent Effects on Glycolysis Are Mediated
by HIF-1a
To determine the contribution of HIF-1a to the glycolytic pheno-
type observed in AMPKa null cells, we stably silenced HIF-1a in
control (Cre–) or AMPKa-deficient (Cre+) MEFs using RNA inter-
ference. Expression of HIF-1a shRNA ablated HIF-1a protein118 Cell Metabolism 17, 113–124, January 8, 2013 ª2013 Elsevier Inc.expression in AMPKa-deficient MEFs
under normoxia (Figure 5A) and blocked
CoCl2-dependent induction of HIF-1aprotein in both AMPKa-deficient and control cells (Figure S5A).
Expression of HIF-1a shRNA reduced pdk1 mRNA in AMPKa-
null cells to control levels, demonstrating that expression of
this shRNA could block HIF-1a-dependent transcription (Fig-
ure 5B). We next determined whether silencing HIF-1a could
reverse the Warburg effect triggered by loss of AMPKa activity.
While HIF-1a shRNA had little effect on the ECAR of control cells,
silencing HIF-1a in AMPKa-deficient cells lowered the ECAR
below control levels (Figure 5C). GC-MS analysis revealed
dramatic reductions in intracellular pyruvate and lactate in
AMPKa-deficient cells expressing HIF-1a shRNA relative to
control shRNA (Figure 5D). Moreover, silencing of HIF-1a
ablated the enhanced levels of glucose consumption (Figure 5E)
and lactate production (Figure 5F) displayed by AMPKa-
deficient cells. Similar reductions in glucose consumption and
lactate production were observed in AMPKa-deficient MEFs
transfected with HIF-1a siRNA (Figures S5B–S5D). Silencing
of Raptor in AMPKa-deficient MEFs, which partially reduced
HIF-1a protein levels (Figure 4I), led to slight reductions in lactate
production (Figure S5E) and ECAR (Figure S5F).
HIF-1a Drives Increased Biosynthesis in
AMPKa-Null Cells
Next we determined the impact of HIF-1a expression on cellular
biosynthesis and proliferation induced by AMPKa loss. Silencing
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Figure 5. HIF-1a Mediates the Effects of
AMPK Loss on Aerobic Glycolysis
(A) HIF-1a protein expression in control (Cre–) or
AMPKa-deficient (Cre+) MEFs also expressing
control or HIF-1a-specific shRNAs. Cells were
grown under normoxic conditions (20% O2).
AMPKa and actin protein levels are shown.
(B) Relative expression of pdk1 mRNA in control
(Cre–) or AMPKa-deficient (Cre+) MEFs express-
ing control (Ctrl) or HIF-1a-specific shRNAs.
(C–F) AMPK-dependent changes in the Warburg
Effect are dependent on HIF-1a.
(C) ECAR of control (Cre–) or AMPKa-deficient
(Cre+) MEFs expressing control (Ctrl) or HIF-
1a-specific shRNAs grown under normoxic
conditions (20% O2).
(D–F) Relative intracellular pyruvate (closed bars)
and lactate (open bars) levels (D), glucose con-
sumption (E), and lactate production (F) for cells
grown as in (C).
Error bars represent the SEM. **p < 0.01, ***p <
0.001. See also Figure S5.
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by approximately 70% (Figure 6A), restoring citrate levels to
that observed in control cells. Moreover, suppression of
HIF-1a dramatically reduced glucose-dependent lipogenesis in
AMPKa-deficient MEFs (Figure 6B). Suppression of HIF-1a had
little effect on glucose-dependent lipogenesis in control cells
(Figure 6B), consistent with the fact that HIF-1a protein is main-
tained at low levels in these cells under normoxia.
Given that aberrant HIF-1a expression drives both enhanced
glycolysis and glucose-derived lipogenesis, we reasoned that
the increased size of AMPKa-deficient cells may be attributed
to HIF-1a-dependent changes in anabolic metabolism. While
loss of AMPKa promotes increased cell size, silencing of
HIF-1a restored the size of AMPKa-deficient MEFs to that of
control cells (Figure 6C). Notably, rapamycin treatment also
reduced the size of AMPKa-deficient MEFs (Figure S6A).
However, this treatment also reduced hif1amRNA levels in cells
regardless of AMPKa expression (Figure S6B), suggesting that
rapamycin may exert its effects in part through regulation of
HIF-1a mRNA. Finally, suppression of HIF-1a signaling inCell Metabolism 17, 113–12AMPKa-deficient cells reduced their
overall rate of proliferation (Figure 6D).
Collectively, the data suggest that
AMPK negatively regulates the metabolic
(Warburg effect) and biosynthetic pro-
grams of proliferating cells through the
inhibition of HIF-1a function.
HIF-1a Is Required for the
Progression of AMPKa1-Deficient
Lymphomas
Our earlier results (Figure 2) indicate that
reduced AMPK signaling synergizes with
Myc to promote the Warburg effect in
lymphoma. To determine the contribution
of HIF-1a to the glycolytic phenotype of
Em-Myc lymphoma cells, we stably ex-pressed HIF-1a-specific shRNAs in Em-Myc lymphoma cells
with silenced AMPKa1. Silencing of HIF-1a in AMPKa1
shRNA-expressing cells reduced HIF-1a protein expression to
control levels (Figure 7A). Protein levels of the HIF-1a targets
Aldolase and LDHA expression also decreased when HIF-1a
was silenced in AMPKa1 shRNA-expressing lymphomas (Fig-
ure 7A). We next examined metabolic activity in these
lymphomas. Expression of AMPKa1 shRNA increased cellular
ECAR as expected, while silencing of HIF-1a reduced this
enhanced ECAR response by 60% (Figure 7B). Finally,
lymphoma cells expressing both AMPKa1 and HIF-1a shRNA
showed decreased proliferation relative to cells expressing
AMPKa1 shRNA alone (Figure 7C).
We next tested the requirement for HIF-1a for tumor progres-
sion in vivo. Primary control or AMPKa-deficient Em-Myc
lymphoma cells were transducedwith retroviral vectors express-
ing GFP and either control or HIF-1a shRNAs, and the per-
centage of GFP+ lymphoma cells (expressing the shRNA of
interest) was determined by flow cytometry prior to transplanta-
tion into recipient mice and after lymphoma formation4, January 8, 2013 ª2013 Elsevier Inc. 119
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Figure 6. HIF-1a Drives Increased Biosyn-
thesis and Proliferation of AMPKa-Null Cells
(A) Relative citrate abundance in metabolite
extracts from AMPKa-deficient (aKO) MEFs ex-
pressing control (Ctrl) or HIF-1a-specific shRNAs
as determined by GC-MS.
(B) Lipid biosynthesis in AMPKa-deficient MEFs
with HIF-1a knockdown. Control (Cre–) or AMPKa-
deficient (Cre+) MEFs expressing control (Ctrl) or
HIF-1a-specific shRNAs were incubated with
uniformly labeled 14C-glucose for 72 hr, and
radioactive counts in extracted lipids were
measured.
(C) Cell size of control (gray histogram), AMPKa-
null (open histogram), and AMPKa-null MEFs
expressing HIF-1a shRNA (dashed histogram) as
measured by FSC intensity.
(D) Growth curves of AMPKa-null MEFs express-
ing control (shCtrl) or HIF-1a-specific (shHIF-1a)
shRNAs grown under 20% O2. Growth curves
were determined using a 3T3 growth protocol and
cell counts measured by trypan blue exclusion.
Error bars represent the SEM. ***p < 0.001. See
also Figure S6.
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AMPK Negatively Regulates the Warburg Effect(Figure 7D). Expression of control shRNA did not dramatically
alter the fraction of GFP+ Em-Myc lymphoma cells regardless
of genotype (Figures 7E and 7F). Interestingly, silencing of HIF-
1a in Em-Myc lymphomas promoted a general increase in the
number of GFP+ tumor cells, although this did not reach statis-
tical significance (Figure 7F). However, lymphoma cells express-
ing HIF-1a shRNA were selectively depleted in AMPKa-null
tumors (Figures 7E and 7F). Collectively, these data suggest
that loss of AMPK signaling promotes a metabolic and growth
advantage in lymphoma cells and that HIF-1a is required for
the growth of AMPKa1 null tumors in vivo.
DISCUSSION
AMPK is a cellular energy sensor that coordinates metabolic
activities in many tissues. Under conditions of energetic stress,
AMPK activation suppresses cell growth and proliferation,
leading to speculation that AMPKmay function as part of a tumor
suppressor pathway (Hardie, 2011; Shackelford and Shaw,
2009). Here we provide genetic evidence that AMPKa displays
tumor suppressor activity in vivo. Loss of AMPK signaling coop-
erates with oncogenicMyc to enhance tumorigenesis in amouse
model of lymphomagenesis, suggesting that AMPK may func-
tion as a tumor suppressor (Figure 1). Moreover, we demonstrate
that AMPK is a negative regulator of both aerobic glycolysis and
cellular biosynthesis in cancer cells. Cells deficient for the cata-
lytic alpha subunit(s) of AMPK display increased aerobic glycol-
ysis marked by increased lactate production from glucose
(Figures 2 and 3), and downregulation of AMPK activity is suffi-
cient to induce the Warburg Effect in cancer cells (Figure 2).
We find that HIF-1a is a key mediator of AMPK-dependent120 Cell Metabolism 17, 113–124, January 8, 2013 ª2013 Elsevier Inc.effects on cellular metabolism. Reduction
of AMPKa levels in cells leads to in-
creased HIF-1a protein levels under
normoxia in both transformed and non-transformed cells (Figure 4), and HIF-1a is required to drive
both the Warburg effect and the growth of AMPKa1-deficient
lymphomas in vivo (Figure 5, 6, and 7). The results presented
here suggest that the downregulation of AMPK activity elimi-
nates a key metabolic checkpoint that normally antagonizes
anabolic progrowth cellular metabolism. Thus, AMPK may act
in cancer cells as a metabolic gatekeeper that functions to
establish metabolic checkpoints that limit cell division, and its
loss of function can enhance both tumorigenesis and tumor
progression.
All cells must manage their energetic resources to survive. We
and others have established that AMPK is the central mediator of
a metabolic cell-cycle checkpoint activated in response to
nutrient limitation in mammalian cells (Gwinn et al., 2008; Inoki
et al., 2003; Jones et al., 2005). However, programs of ATP
production and macromolecular synthesis must also be coordi-
nated in proliferating cells to ensure proper cell division. The data
presented here suggest that AMPK functions to regulate meta-
bolic homeostasis in proliferating cells in the absence of acute
energetic stress. Isogenic MEFs or cancer cells lacking AMPKa
activity display a metabolic shift toward aerobic glycolysis, thus
allowing cancer cells to engage aerobic glycolysis for ATP
production and divert glucose-derived CAC intermediates
toward lipid biosynthesis to support increased cell growth.
AMPK may also influence lipid biosynthesis through regulation
of ACC and other lipogenic enzymes, possibly through its effects
on SREBP-1 (Li et al., 2011). Thus, defective AMPKa signaling
promotes the rewiring ofmetabolic pathways to favor cell growth
pathways.
Interestingly our data provide evidence that AMPKa-deficient
tumors display increased activation of the TORC1 targets S6 and
A B C
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Figure 7. HIF-1a Mediates the Metabolic
and Tumorigenic Effects Induced by
AMPKa1 Loss
(A) Immunoblots of whole-cell lysates from Em-
Myc lymphoma cells expressing AMPKa1 and
HIF-1a shRNAs. Cells were cultured under stan-
dard conditions (25 mM glucose, 20% O2). Blots
were probed with antibodies to the indicated
proteins.
(B) ECAR of Em-Myc lymphoma cells expressing
control (Ctrl), AMPKa1 (a1), or both AMPKa1 and
HIF-1a (a1/HIF-1a) shRNAs and grown under
standard conditions.
(C) Competition assay of Em-Myc lymphoma
cells infected with retrovirus expressing GFP
and control, AMPKa1 (a1), or both AMPKa1 and
HIF-1a (a1/HIF-1a) shRNAs. The data are ex-
pressed as the relative increase in GFP+ to GFP-
cells after 6 days of culture.
(D) Schematic of in vivo lymphoma competition
assay.
(E) Representative histograms of GFP expression
for AMPKa1/ Em-Myc lymphoma cells prior
to injection into recipient mice (preinjection,
black) or isolated from lymph node tumors (tumor,
red). Numbers indicate the percentage of GFP+
cells.
(F) Percent recovery of GFP+ tumor cells from
individual Em-Myc/a1+/+ (black) or Em-Myc/a1/
(white) tumors expressing the indicated shRNAs.
Error bars represent the SEM. *p < 0.05.
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AMPK Negatively Regulates the Warburg Effect4E-BP1, suggesting that AMPK, as opposed to other AMPK-
related kinases, may be the key TORC1 regulator downstream
of LKB1 in tumors. Consistent with past work (Inoki et al.,
2003; Liu et al., 2006; Shaw et al., 2004a), we find that AMPK
functions to downregulate TORC1 activity specifically under
conditions of energetic stress, when it is desirable to suppress
ATP-consuming processes such as mRNA translation. This
may provide a metabolic advantage to proliferating cells, where
the loss of AMPK signaling promotes increased ATP production
and resource accumulation without affecting the mitogenic
properties of TORC1. By concurrently silencing AMPK while
maintaining TORC1 signaling, cells may effectively bypass
endogenous brakes on cellular metabolism, supporting
increased tumor cell growth and proliferation.
Our work here establishes HIF-1a as a key mediator of the
metabolic transformation triggered by reduced AMPKa activity
in cancer cells. We show that downregulation of AMPK signaling
is sufficient to induce normoxic HIF-1a stabilization and enhance
the Warburg effect. TORC1 activity appears to contribute in part
to this process, as silencing of the mTORC1 binding partner
Raptor reduces levels of hif1a mRNA in AMPKa-deficient cells.
However, silencing of Raptor moderately reduces HIF-1a protein
levels and has a minimal effect on the glycolytic phenotype of
AMPKa-deficient cells, suggesting that AMPK may regulate
HIF-1a-dependent Warburg metabolism through additional
mechanisms. Interestingly, TORC1 inhibition reduces hif1a
mRNA and reduces glycolysis in cells regardless of AMPK
expression, suggesting that TORC1 may function on a moreCellglobal level as a positive regulator of glycolysis beyond specific
effects on HIF-1a expression (Du¨vel et al., 2010). Given that
TORC1 signaling is elevated in AMPKa1-deficient lymphomas,
this may have implications for tumor metabolism in vivo.
HIF-1a mRNA levels are unaffected by AMPK expression; thus,
AMPK may affect normoxic HIF-1a protein expression either
through decreased protein turnover or differential translation of
HIF-1a mRNA (Choo et al., 2008). Overall, we propose that
AMPK functions to coordinate glycolytic and oxidative metabo-
lism in proliferating cells by restricting HIF-1a function.
One consequence of AMPK loss in cells is enhanced flux of
glucose-derived carbon to citrate for lipid biosynthesis, pro-
moting biomass accumulation and increased cell size. This
may appear to be counterintuitive, as HIF-1a-dependent
upregulation of PDK1 under hypoxia is proposed to direct
glucose-derived carbon away from the CAC (Kim et al., 2006;
Papandreou et al., 2006). However, glucose-to-citrate flux is
not blocked in AMPKa-null cells, despite elevated PDK1 levels.
Rather, the reduced levels of citrate(m+4) in AMPKa-null cells
may result from increased use of glucose-derived citrate(m+2)
for lipid biosynthesis. Reduction of AMPK levels significantly
decreases ACC1 inhibition in both tumor cells and tumor tissue,
which would permit maximal activity of ACC1 for lipid biosyn-
thesis. Thus, AMPKmay regulate lipid biosynthesis and biomass
accumulation on multiple levels: substrate availability (HIF-1a-
dependent glucose-derived citrate) and ACC activity.
We propose that AMPK may function as a metabolic tumor
suppressor, limiting the growth of cancer cells by regulatingMetabolism 17, 113–124, January 8, 2013 ª2013 Elsevier Inc. 121
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unchecked proliferation. Thus, selection against AMPK activity
may represent an important regulatory step for tumor initiation
and progression, allowing tumor cells to gain a metabolic growth
advantage. ReducedAMPKactivity hasbeendetected in primary
human breast cancer (Hadad et al., 2009), and reduced expres-
sion of prkaa2, the gene that encodes for AMPKa2, has been
linked to human breast, ovarian, and gastric cancer (Hallstrom
et al., 2008; Kim et al., 2012). It is also well documented that
LKB1 deficiency (Shackelford and Shaw, 2009) or genetic events
that target LKB1 activity (Godlewski et al., 2010; Zheng et al.,
2009) lead to reduced AMPK signaling in tumor cells. Thus, there
may be several routes by which AMPK function is suppressed in
tumors to provide a selective metabolic growth advantage.
While selection for loss of AMPK function may favor the War-
burg effect in tumor cells, it may also eliminate metabolic check-
points essential for cellular adaptation to stress. AMPK normally
plays a protective role to block cell growth in response to poor
nutrient conditions, and as such its loss or suppression during
tumorigenesis may sensitize tumor cells to apoptosis under
hypoxic or nutrient depleted environments (Svensson and
Shaw, 2012). Consistent with this, silencing AMPKa1 in Em-
Myc lymphomas conferred sensitivity to apoptosis induced by
the glycolytic inhibitor 2-DG. The increased levels of ACC phos-
phorylation observed in Em-Myc tumors (Figure 1) imply that
lymphomas experience metabolic stress and AMPK activation
in vivo. Thus, while ablation of AMPK signaling may enhance
tumorigenesis, inhibition of this central energy-sensing pathway
may offer unique a therapeutic window for the treatment of
tumors with metabolic inhibitors. Our data provide amechanistic
rationale in support of the use of AMPK agonists such as metfor-
min for cancer therapy (Buzzai et al., 2007; Evans et al., 2005), as
the efficacy of these agents against tumor growth may lie in their
ability to engage AMPK-dependent metabolic checkpoints to
restrict anabolic growth. Understanding the reprogramming of
cellular metabolic networks by AMPK in cancer may aid in the
development of novel approaches for cancer therapy.
EXPERIMENTAL PROCEDURES
Cell Lines, DNA Constructs, and Cell Culture
PrimaryMEFsdeficient forprkaa1 (a1/) and conditional for prkaa2 (a2fl/fl) were
generated by timed mating as previously described (Jones et al., 2005) and
immortalized with SV40 Large T Antigen. HCT116 cells were obtained from
ATCC. Primary Em-Myc lymphoma cellswere provided by Jerry Pelletier (Robert
et al., 2009). DNA plasmids MiCD8t, pKD-HIF-1a hp, and LMP-based shRNAs
against mouse and human AMPKa1 and a2 have been described previously
(Bungard et al., 2010; Jones et al., 2005; Lum et al., 2007). AMPKa-deficient
MEFsweregeneratedby transduction ofa1/,a2fl/flMEFswithCre-expressing
retrovirus to delete a2-floxed alleles. For siRNA transfections, cells were sub-
jected to two rounds of reverse transfection with pooled siRNAs against HIF-
1a (Dharmacon) with Lipofectamine RNAimax (Hatzivassiliou et al., 2005).
AMPKactivitywasassessed incell linesafter stimulationwithAICAR (1mM,Tor-
onto Research Chemicals) or metformin (5 mM, Sigma) for 1 hr. For induction of
HIF-1a protein expression, cells were treated with CoCl2 (100 mM) for 1 hr. For
mass isotopomer analysis, cells were incubated in glucose- or glutamine-free
medium containing 10% dialyzed FBS and uniformly labeled [13C]-glucose or
[13C]-glutamine, respectively (Cambridge Isotope Laboratories).
Mice
Mice deficient for AMPKa1 (Mayer et al., 2008), floxed for AMPKa2 (Jørgensen
et al., 2004), and Em-Myc transgenic mice (Adams et al., 1985) have been122 Cell Metabolism 17, 113–124, January 8, 2013 ª2013 Elsevier Indescribed previously. Em-Myc/a1/ mice (and littermate controls) were
generated by breeding of AMPKa1-deficient and Em-Myc transgenic mouse
strains. Mice were bred and maintained under specific pathogen-free condi-
tions at McGill University under approved protocols.
Determination of Cell Proliferation, Competition Assays,
and Cell Size
Cell proliferation curves for all cell lines was determined by cell counting with
trypan blue exclusion and a TC10Automated Cell Counter (BioRad). For in vitro
competition assays, primary Em-Myc lymphoma cells were transduced with
retroviral vectors coexpressing GFP and AMPKa1-specific shRNA or control
shRNA, and the percentage of GFP-positive cells remaining after 6 days
of culture was determined by flow cytometry. Cell size of viable cells was
quantified as the mean fluorescence intensity for FSC with flow cytometry.
All flow cytometry was conducted with BD FACSCalibur (BD Biosciences)
or Gallios (Beckman Coulter) flow cytometers and analyzed with FlowJo
software (Tree Star).
Immunoblotting
Cells were lysed in modified CHAPS buffer (10 mM Tris-HCl, 1 mM MgCl2,
1 mM EGTA, 0.5 mM CHAPS, 10% glycerol, and 5 mM NaF) or AMPK lysis
buffer (MacIver et al., 2011) supplemented with protease and phosphatase
inhibitors (Roche), DTT (1 mg/ml), and benzamidine (1 mg/ml). Cleared lysates
were resolved by SDS-PAGE, transferred to nitrocellulose, and incubated
with primary antibodies. Primary antibodies to AMPK (pT172-specific and
total), AMPKa2, ACC (pS79 and total), p70 S6 kinase (pT389-specific and
total), S6 ribosomal protein (pS235/236-specific and total), 4E-BP1 (pT37/
46-specific and total), LDHA, PDK1, Aldolase, and actin were obtained from
Cell Signaling Technology. Anti-HIF-1a antibodies were from Cayman
Biomedical.
Quantitative Real-Time PCR
Total mRNA was isolated from cells with Trizol, and complementary DNA
(cDNA) was synthesized from 100 ng total RNA with the Superscript VILO
cDNA Synthesis Kit (Invitrogen). Quantitative PCR was performed with
SYBR Green qPCR SuperMix (Invitrogen) and an Mx3005 qPCR machine
(Agilent Technologies) with primers against aldoA, ldha, pdk1, hif1a, and actin.
All samples were normalized to b-actin mRNA levels. Primer sequences are
listed in Table S1.
Metabolic Assays
Respirometry (OCR) and the extracellular acidification rate (ECAR) of
cells were measured with an XF24 Extracellular Flux Analyzer (Seahorse
Bioscience). In brief, cells were plated at 5 3 104/well in 625 ml nonbuffered
Dulbecco’s modified Eagle’s medium containing 25 mM glucose and 2 mM
glutamine. Cells were incubated in a CO2-free incubator at 37
C for 1 hr to
allow for temperature and pH equilibration prior to loading into the XF24
apparatus. XF assays consisted of sequential mix (3 min), pause (3 min),
and measurement (5 min) cycles, allowing for determination of OCR/ECAR
every 10 min.
Glucose consumption and lactate production were determined via enzy-
matic assays described previously (Buzzai et al., 2007). Glucose-derived lipid
biosynthesis was determined by culturing of cells in medium containing
14C-glucose for 3 days, and extracted lipids with a 1:1:1 Water/Methanol/
Chloroform extraction procedure (Mullen et al., 2012). After extraction, the
organic layer was isolated, dried via N2 stream, resuspended in methanol,
and incorporated radioactivity measured with a MicroBeta Liquid Scintillation
Counter (Perkin Elmer).
Analysis of Metabolites by NMR and GC-MS
Metabolites from tissue culture cells were extracted as described previously
(Xu et al., 2011). In brief, cells (2–53 106/10 cm dish) were washed three times
with ice-cold 0.9% saline solution. Cells were lysed with ice-cold 80% meth-
anol followed by sonication (Diagenode Bioruptor), and extracts were dried
by vacuum centrifugation. For NMR analysis, cell extracts were resuspended
in 220 ml 2H2O containing 0.2 mM 4,4-dimethyl-4-silapentane-1-sulfonic acid
(DSS), 0.1 mM difluorotrimethylsilanylphosphonic acid (DFTMP), and 0.01 mM
sodium azide. NMR data collection was performed at the Que´bec/Easternc.
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AMPK Negatively Regulates the Warburg EffectCanada High Field NMR Facility on a 500 MHz Inova NMR system (Agilent
Technologies) equipped with an HCN cryogenically cooled probe operating
at 25 K. Metabolite chemical shift assignments were confirmed by total corre-
lation spectroscopy, and targeted metabolites were profiled with a 500 MHz
metabolite library from Chenomx.
For GC-MS analysis, dried samples were resuspended in 30 ml anhydrous
pyridine and added to GC-MS autoinjector vials containing 70 ml N-(tert-butyl-
dimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA) derivatization reagent.
The samples were incubated at 70C for 1 hr, after which aliquots of 1 ml
were injected for analysis. GC-MS data were collected on an Agilent 5975C
series GC/MSD system (Agilent Technologies) operating in election ionization
mode (70 eV) and selected ion monitoring. Quantified metabolites were
normalized relative to protein content (mg).
Statistical Analysis
Statistics were determined with a paired Student’s t test, ANOVA, or log-rank
(Mantel-Cox) test with Prism software (GraphPad). Data are calculated as the
mean ± SEMunless otherwise indicated. Statistical significance is represented
in figures by *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and one table and can be found
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